Xellia Sustainability Profile
Xellia Pharmaceuticals, commonly referred to as Xellia, is a leading global provider of specialty pharmaceuticals, headquartered in Denmark (DK). Founded in 2008, the company has established a strong presence in the development and manufacturing of anti-infective products, particularly focusing on injectable antibiotics and other critical care medications. With operational facilities in Europe and North America, Xellia is renowned for its commitment to quality and innovation in the pharmaceutical industry. The company’s core offerings include a range of high-potency injectable drugs, which are distinguished by their efficacy and safety profiles. Xellia has achieved significant milestones, including regulatory approvals and partnerships that enhance its market position. As a trusted supplier to healthcare providers worldwide, Xellia continues to play a vital role in addressing global health challenges through its specialised pharmaceutical solutions.
DitchCarbon Score
How does Xellia's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Xellia's score of 38 is higher than 63% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Xellia's reported carbon emissions
In 2022, Xellia Pharmaceuticals AS reported total carbon emissions of approximately 244.96 million kg CO2e. This figure includes Scope 1 emissions of about 6.47 million kg CO2e, Scope 2 emissions of approximately 15.91 million kg CO2e, and Scope 3 emissions totalling around 222.58 million kg CO2e. Xellia has set ambitious climate commitments, aiming for net-zero emissions across all scopes by 2045. Specifically, the company has pledged to achieve zero emissions from its operations and transportation (Scope 1 and 2) by 2030. Additionally, Xellia targets a 33% reduction in Scope 3 emissions by 2033, compared to a 2024 baseline. These commitments reflect Xellia's dedication to sustainability and align with industry standards for climate action. The emissions data is not cascaded from any parent organization, indicating that these figures are independently reported by Xellia Pharmaceuticals AS.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | |
|---|---|---|
| Scope 1 | 7,256,000 | 0,000,000 |
| Scope 2 | 16,258,000 | 00,000,000 |
| Scope 3 | 127,920,000 | 000,000,000 |
How Carbon Intensive is Xellia's Industry?
How Carbon Intensive is Xellia's Location?
Xellia's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Xellia has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
